The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
Open accessAbstract
SUMMARY MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. Most notably, MI-2 was nontoxic to mice, and displayed selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-DLBCL tumors in vivo. The compound was also effective against primary human non-germinal center B cell-like DLBCLs ex vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationHans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationRosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationIrreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090 · cited 2×
“…MI-2 was found to be a potent, selective, and irreversible MALT1 inhibitor, analogous to protease inhibitor drugs such as telaprevir against the NS3/4A protease of hepatitis C virus (Klibanov et al., 2011), the proteasome inhibitor carfilzomib (Genin et al., 2010), and others (Powers et al., 2002).”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Self-citationA Unified Model for Apical Caspase Activation
Boatright, K. M., Renatus, M., Scott, F. L., Sperandio, S., Shin, H., Pedersen, I. M., Ricci, J.-E., Edris, W. A., Sutherlin, D. P., Green, D. R., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00051-0 · Cited by 968
Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Self-citationDierlamm, J., Baens, M., Wlodarska, I., Stefanova-Ouzounova, M., Hernandez, J. M., Hossfeld, D. K., De Wolf-Peeters, C., Hagemeijer, A., Van den Berghe, H., & Marynen, P. (1999) · Blood · doi:10.1182/blood.v93.11.3601 · Cited by 718
A loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Crystal structure of the cysteine protease interleukin-1β-converting enzyme: A (p20/p10)2 homodimer
Walker, N. P. C., Talanian, R. V., Brady, K. D., Dang, L. C., Bump, N. J., Ferenza, C. R., Franklin, S., Ghayur, T., Hackett, M. C., Hammill, L. D., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90303-4 · Cited by 576
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma
Streubel, B., Lamprecht, A., Dierlamm, J., Cerroni, L., Stolte, M., Ott, G., Raderer, M., & Chott, A. (2003) · Blood · doi:10.1182/blood-2002-09-2963 · Cited by 493
Coornaert, B., Baens, M., Heyninck, K., Bekaert, T., Haegman, M., Staal, J., Sun, L., Chen, Z. J., Marynen, P., & Beyaert, R. (2008) · Nature Immunology · doi:10.1038/ni1561 · Cited by 434
Lucas, P. C., Yonezumi, M., Inohara, N., McAllister-Lucas, L. M., Abazeed, M. E., Chen, F. F., Yamaoka, S., Seto, M., & Núñez, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009984200 · Cited by 421
Differential Requirement for Malt1 in T and B Cell Antigen Receptor Signaling
Ruland, J., Duncan, G. S., Wakeham, A., & Mak, T. W. (2003) · Immunity · doi:10.1016/s1074-7613(03)00293-0 · Cited by 390
Regulation of NF-κB-Dependent Lymphocyte Activation and Development by Paracaspase
Ruefli-Brasse, A. A., French, D. M., & Dixit, V. M. (2003) · Science · doi:10.1126/science.1090769 · Cited by 379
The proteolytic activity of the paracaspase MALT1 is key in T cell activation
Rebeaud, F., Hailfinger, S., Posevitz-Fejfar, A., Tapernoux, M., Moser, R., Rueda, D., Gaide, O., Guzzardi, M., Iancu, E. M., Rufer, N., et al. (2008) · Nature Immunology · doi:10.1038/ni1568 · Cited by 310
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas
Honma, K., Tsuzuki, S., Nakagawa, M., Tagawa, H., Nakamura, S., Morishima, Y., & Seto, M. (2009) · Blood · doi:10.1182/blood-2008-12-194852 · Cited by 305
The Apoptosome Activates Caspase-9 by Dimerization
Pop, C., Timmer, J., Sperandio, S., & Salvesen, G. S. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.009 · Cited by 294
Polo, J. M., Dell'Oso, T., Ranuncolo, S. M., Cerchietti, L., Beck, D., Da Silva, G. F., Prive, G. G., Licht, J. D., & Melnick, A. (2004) · Nature Medicine · doi:10.1038/nm1134 · Cited by 291
Self-citationA Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288
Self-citationHailfinger, S., Nogai, H., Pelzer, C., Jaworski, M., Cabalzar, K., Charton, J.-E., Guzzardi, M., Décaillet, C., Grau, M., Dörken, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105020108 · Cited by 240
T‐cell receptor‐induced JNK activation requires proteolytic inactivation of CYLD by MALT1
Staal, J., Driege, Y., Bekaert, T., Demeyer, A., Muyllaert, D., Van Damme, P., Gevaert, K., & Beyaert, R. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.85 · Cited by 219
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
Hailfinger, S., Lenz, G., Ngo, V., Posvitz-Fejfar, A., Rebeaud, F., Guzzardi, M., Penas, E.-M. M., Dierlamm, J., Chan, W. C., Staudt, L. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907511106 · Cited by 204
Ferch, U., Kloo, B., Gewies, A., Pfänder, V., Düwel, M., Peschel, C., Krappmann, D., & Ruland, J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091167 · Cited by 203
Sanchez-Izquierdo, D. (2003) · Blood · doi:10.1182/blood-2002-10-3236 · Cited by 191
Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma
Farinha, P., & Gascoyne, R. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.011 · Cited by 184
Self-citationA peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Cerchietti, L. C., Yang, S. N., Shaknovich, R., Hatzi, K., Polo, J. M., Chadburn, A., Dowdy, S. F., & Melnick, A. (2009) · Blood · doi:10.1182/blood-2008-07-168773 · Cited by 183
Self-citationPathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies
Lim, K., Yang, Y., & Staudt, L. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01105.x · Cited by 157
Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Génin, E., Reboud‐Ravaux, M., & Vidal, J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790725515 · Cited by 129
Cerchietti, L. C. A., Hatzi, K., Caldas-Lopes, E., Yang, S. N., Figueroa, M. E., Morin, R. D., Hirst, M., Mendez, L., Shaknovich, R., Cole, P. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42869 · Cited by 121
Self-citationNaylor, T. L., Tang, H., Ratsch, B. A., Enns, A., Loo, A. T., Chen, L., Lenz, P., Waters, N. J., Schüler, W., Dörken, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2525 · Cited by 119
Groß, O., Grupp, C., Steinberg, C., Zimmermann, S., Strasser, D., Hannesschläger, N., Reindl, W., Jonsson, A. H., Huo, H., Littman, D. R., et al. (2008) · Blood · doi:10.1182/blood-2007-11-123513 · Cited by 117
Structural Determinants of MALT1 Protease Activity
Wiesmann, C., Leder, L., Blank, J., Bernardi, A., Melkko, S., Decock, A., D'Arcy, A., Villard, F., Erbel, P. J. A., Hughes, N., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.02.018 · Cited by 103
Mechanism and specificity of the human paracaspase MALT1
Hachmann, J., Snipas, S. J., van Raam, B. J., Cancino, E. M., Houlihan, E. J., Poręba, M., Kasperkiewicz, P., Drąg, M., & Salvesen, G. S. (2012) · Biochemical Journal · doi:10.1042/bj20120035 · Cited by 90
Caspase-9 Holoenzyme Is a Specific and Optimal Procaspase-3 Processing Machine
Yin, Q., Park, H. H., Chung, J. Y., Lin, S., Lo, Y.-C., da Graca, L. S., Jiang, X., & Wu, H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.030 · Cited by 89
Self-citationYu, J. W., Jeffrey, P. D., Ha, J. Y., Yang, X., & Shi, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111708108 · Cited by 88
Ferch, U., Büschenfelde, C. M. Z., Gewies, A., Wegener, E., Rauser, S., Peschel, C., Krappmann, D., & Ruland, J. (2007) · Nature Immunology · doi:10.1038/ni1493 · Cited by 81
Vicente‐Dueñas, C., Fontán, L., González‐Herrero, I., Romero-Camarero, I., Segura, V., Aznar, M. A., Alonso-Escudero, E., Campos‐Sánchez, E., Ruiz-Roca, L., Barajas-Diego, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204127109 · Cited by 78
Self-citationDierlamm, J., Penas, E. M. M., Bentink, S., Weßendorf, S., Berger, H., Hummel, M., Klapper, W., Lenze, D., Rosenwald, A., Haralambieva, E., et al. (2008) · Haematologica · doi:10.3324/haematol.12057 · Cited by 45
Matz, M., Naik, M. G., Mashreghi, M., Glander, P., Neumayer, H., & Budde, K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.540238 · Cited by 35
Cited by
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins
Fu, M., & Blackshear, P. J. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.129 · Cited by 340
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Metadata
- Authors
- Fontan, L., Yang, C., Kabaleeswaran, V., Volpon, L., Osborne, M. J., Beltran, E., Garcia, M., Cerchietti, L., Shaknovich, R., Yang, S. N., Fang, F., Gascoyne, R. D., Martinez-Climent, J. A., Glickman, J. F., Borden, K., Wu, H., & Melnick, A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 22
- Issue
- 6
- Pages
- 812-824
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1990045094
- Cited by
- 264
- References
- 52
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.